OPK Stock Overview
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for OPK from our risk checks.
OPKO Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.53 |
| 52 Week High | US$2.24 |
| 52 Week Low | US$1.00 |
| Beta | 1.84 |
| 1 Month Change | 13.33% |
| 3 Month Change | -12.07% |
| 1 Year Change | 7.75% |
| 3 Year Change | -66.67% |
| 5 Year Change | -53.92% |
| Change since IPO | -66.00% |
Recent News & Updates
Recent updates
Is OPKO Health (NASDAQ:OPK) A Risky Investment?
Oct 03
OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up
Jul 24Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?
Jun 07Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?
Jan 04OPKO Health: Assessing If Significant Potential Can Be Realized
Sep 15OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
Sep 05OPKO Health: 14%+ Short Interest Means More Volatility Over The Near Term
Jun 21OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
Apr 29OPKO Health: A Great Long-Term Investment In Health
Apr 05OPKO Health Is Risky But Might Make You Money
Mar 29Analysts Have Just Cut Their OPKO Health, Inc. (NASDAQ:OPK) Revenue Estimates By 14%
Feb 27OPKO Health (NASDAQ:OPK) Has A Pretty Healthy Balance Sheet
Jan 12OPKO Health: Undervalued Opportunity
Dec 23OPKO Health: Bullish Case Still Intact
Dec 15We Think OPKO Health (NASDAQ:OPK) Can Stay On Top Of Its Debt
Sep 27OPKO Health: A Defensive, Long-Term Holding
Sep 19Downgrade: Here's How Analysts See OPKO Health, Inc. (NASDAQ:OPK) Performing In The Near Term
Aug 03OPKO Health: Looking For Buyers To Enter At The $3.50 Level (Support)
Jul 14These 4 Measures Indicate That OPKO Health (NASDAQ:OPK) Is Using Debt Reasonably Well
Jun 11OPKO Health perks up amid insider purchase
May 26COVID-19 testing strength helps OPKO's Q1 results surge
Apr 28Shareholder Returns
| OPK | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -2.5% | -0.5% | 1.1% |
| 1Y | 7.7% | -6.2% | 11.7% |
Return vs Industry: OPK exceeded the US Healthcare industry which returned -6.2% over the past year.
Return vs Market: OPK underperformed the US Market which returned 11.7% over the past year.
Price Volatility
| OPK volatility | |
|---|---|
| OPK Average Weekly Movement | 6.1% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: OPK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: OPK's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 4,196 | Phil Frost | https://www.opko.com |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.
OPKO Health, Inc. Fundamentals Summary
| OPK fundamental statistics | |
|---|---|
| Market Cap | US$1.18b |
| Earnings (TTM) | -US$207.61m |
| Revenue (TTM) | US$866.93m |
1.4x
P/S Ratio-5.7x
P/E RatioIs OPK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPK income statement (TTM) | |
|---|---|
| Revenue | US$866.93m |
| Cost of Revenue | US$627.24m |
| Gross Profit | US$239.69m |
| Other Expenses | US$447.30m |
| Earnings | -US$207.61m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 27.65% |
| Net Profit Margin | -23.95% |
| Debt/Equity Ratio | 17.4% |
How did OPK perform over the long term?
See historical performance and comparison